Please assess the completion status of the following clinical trial:

Trial Title: Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum Uric Acid ≥6.0 mg/dL~* eGFR ≥30 mL/min/1.73 m2~* UACR between 30 mg/g and 3500 mg/g inclusive~* Diagnosed with T2DM~Exclusion Criteria:~* Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat) and URAT1 inhibitors (lesinurad, verinurad, probenecid, and benzbromarone)~* Prior history of gout, unless prophylaxis therapy isn't required~* Patients who are pregnant, lactating, or planning to become pregnant~* Patients unsuitable or unable to undergo MRI assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Verinurad 9 mg+Febuxostat 80 mg (Type: EXPERIMENTAL): Capsule administered orally, once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Capsule administered orally, once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).